Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab
Article first published online: 7 DEC 2010
© 2010 Blackwell Publishing Ltd
Alimentary Pharmacology & Therapeutics
Volume 33, Issue 3, pages 340–348, February 2011
How to Cite
Taxonera, C., Estellés, J., Fernández-Blanco, I., Merino, O., Marín-Jiménez, I., Barreiro-de Acosta, M., Saro, C., García-Sánchez, V., Gento, E., Bastida, G., Gisbert, J. P., Vera, I., Martinez-Montiel, P., Garcia-Morán, S., Sánchez, M. C. and Mendoza, J. L. (2011), Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Alimentary Pharmacology & Therapeutics, 33: 340–348. doi: 10.1111/j.1365-2036.2010.04531.x
- Issue published online: 4 JAN 2011
- Article first published online: 7 DEC 2010
- Publication data Submitted 11 August 2010 First decision 15 September 2010 Resubmitted 12 November 2010 Accepted 15 November 2010 EV Pub Online 7 December 2010
Aliment Pharmacol Ther 2011; 33: 340–348
Background The long-term efficacy of adalimumab in patients with ulcerative colitis is not well known.
Aim To evaluate the short- and long-term outcomes of adalimumab in ulcerative colitis patients previously treated with infliximab.
Methods Patients with active ulcerative colitis were treated with adalimumab after failure of other therapies including infliximab. Short-term clinical response and remission were assessed at weeks 4 and 12. The proportion of patients who continued on adalimumab and the proportion of patients who remained colectomy free were assessed over the long term.
Results Clinical response at weeks 4 and 12 was achieved in 16 (53%) and 18 (60%) patients, respectively, and clinical remission was obtained in 3 (10%) and 8 (27%) patients, respectively. After a mean 48 weeks’ follow-up, 15 patients (50%) continued on adalimumab. Six patients (20%) required colectomy. All patients who achieved clinical response at week 12 were colectomy free at long term.
Conclusions Adalimumab was well tolerated and induced durable clinical response in many patients with otherwise medically refractory ulcerative colitis. Patients achieving clinical response at week 12 avoided colectomy over the long term.